Details of the Drug Combination

General Information of Drug Combination (ID: DCDQN5K)

Drug Combination Name
BRL-15572 Diethylcarbamazine
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs BRL-15572   DMM61Y2 Diethylcarbamazine   DM1TJ8F
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 32.52
Bliss Independence Score: 32.52
Loewe Additivity Score: 44.07
LHighest Single Agent (HSA) Score: 44.07

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of BRL-15572
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [2]
BRL-15572 Interacts with 9 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
5-HT 1B receptor (HTR1B) TTK8CXU 5HT1B_HUMAN Agonist [5]
5-HT 1D receptor (HTR1D) TT6MSOK 5HT1D_HUMAN Agonist [5]
5-HT 6 receptor (HTR6) TTJS8PY 5HT6R_HUMAN Agonist [5]
5-HT 2B receptor (HTR2B) TT0K1SC 5HT2B_HUMAN Agonist [5]
5-HT 2A receptor (HTR2A) TTJQOD7 5HT2A_HUMAN Agonist [5]
5-HT 1F receptor (HTR1F) TT0MI3F 5HT1F_HUMAN Agonist [5]
5-HT 1A receptor (HTR1A) TTSQIFT 5HT1A_HUMAN Agonist [5]
5-HT 2C receptor (HTR2C) TTWJBZ5 5HT2C_HUMAN Agonist [5]
5-HT 1E receptor (HTR1E) TTCPG9S 5HT1E_HUMAN Agonist [5]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 DTT(s)
Indication(s) of Diethylcarbamazine
Disease Entry ICD 11 Status REF
Elephantiasis N.A. Approved [3]
Loiasis N.A. Approved [3]
Lymphatic filariasis 1F66.3 Approved [4]
Onchocerciasis 1F6A Approved [3]
Diethylcarbamazine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Arachidonate 5-lipoxygenase (5-LOX) TT2J34L LOX5_HUMAN Inhibitor [6]
------------------------------------------------------------------------------------
Diethylcarbamazine Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 2C19 (CYP2C19) OTFMJYYE CP2CJ_HUMAN Increases Activity [7]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 10).
3 Diethylcarbamazine FDA Label
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):312-20.
6 Inhibition of leukotriene formation by diethylcarbamazine modifies the acid-base balance in the rabbits with blast injuries of the lungs. Vojnosanit Pregl. 1999 May-Jun;56(3):243-7.
7 Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.